Particle Size Reduction: Identifying the Potential & Benefits for Micronization

Sponsored by: Catalent Pharma Solutions

Focused on:

  • Bioavailability
  • Particle Size Reduction

Date: 23 August


Time: 3PM London/10AM New York

Bioavailability is a constant topic in pharmaceutical development; one that has several technology options to choose from when developing a poorly soluble compound [Developability Classification System (DCS) Class II and V]. Molecules within DCS Class IIa have a slow dissolution rate that limits their solubilization and absorption. Particle size reduction technologies such as micronization are commonly used in the industry to overcome this limitation. Co-micronization is an advancement in the traditional micronization process where an excipient is blended with an API prior to micronization. Advantages include decreased agglomeration, avoidance of dry blending, enhanced hydrophilic character and solubility, enhanced dissolution rate, and better flow properties.

Presented by

Stephen Tindal,

Director, Science & Technology, USA

Stephen Tindal is the Director, Science & Technology for Catalent Pharma Solutions. He holds a Bachelor’s degree in Chemistry and Analytical Sciences from Loughborough, UK. Stephen has worked at Catalent for 30 years, holding positions in R&D responsible for formulation, process development, and clinical and commercial operations.

Peter Nelson,

Technical Operations Director

Peter Nelson is the Technical Operations Director at Catalent Micron Technologies. He holds a Bachelor’s degree in Biology from Gettysburg College. Peter has worked at Catalent for 21 years, holding positions in Quality Control and Analytical Services department supporting contract micronization and stand-alone analytical services with an emphasis on solid-state characterization.

Key Learning Objectives

  • Basics of how particle size reduction improves solubilization and bioavailability
  • How to identify if micronization is the right path to take for your molecule
  • Scale-up from prototype to phase I and beyond
  • The benefits of co-micronization


  • Director of Analytical Chemistry
  • Director of API Manufacturing
  • Vice President of API Manufacturing
  • Process Development Engineers/Scientists
  • Associate Director of R&D
  • Director of R&D
  • Head of Medicinal Chemistry
  • Senior Director of CMC
  • Director of Pharmaceutical Sciences
  • Director of Chemical Development
  • Head of Analytical Services